Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baclofen dose-ranging trial for alcohol use disorder in patients with liver cirrhosis
ISRCTN17435333Phase 3Active, not recruiting
- Sponsor
- University of Liverpool
- Start
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of baclofen in alcohol use disorder (AUD) (4 arms), sponsored by University of Liverpool. Primary endpoint: Continued abstinence post randomisation for 24 weeks. Started Mar 2024; status: active, not recruiting.
02
Drugs
baclofen
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on ISRCTN17435333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17435333.